NasdaqGM:ACIUBiotechs
AC Immune (NasdaqGM:ACIU): Exploring Valuation Following Promising Phase 1b/2a Alzheimer’s Data Publication
AC Immune (NasdaqGM:ACIU) just shared peer-reviewed data from its Phase 1b/2a trial of ACI-35.030, an active immunotherapy targeting Tau in early Alzheimer's, developed with Janssen. The findings highlight a rapid and sustained antibody response as well as a clean safety profile.
See our latest analysis for AC Immune.
With this encouraging clinical update, AC Immune is starting to turn heads, especially as the company’s latest innovation underscores its growing potential in Alzheimer’s...